Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | APG-1252 |
Synonyms | |
Therapy Description |
Pelcitoclax (APG-1252) inhibits BCL2 and BCL-XL, which potentially leads to tumor growth inhibition (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 9116). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
APG-1252 | BM-1252|Pelcitoclax|APG1252|APG 1252 | BCL-XL inhibitor 14 BCL2 inhibitor 27 | Pelcitoclax (APG-1252) inhibits BCL2 and BCL-XL, which potentially leads to tumor growth inhibition (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 9116). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03080311 | Phase I | APG-1252 | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors | Completed | USA | 0 |